Kallistatin is a potent new vasodilator

Journal of Clinical Investigation

Volumn 100, Issue 1, 1997, Pages 11-17

  Chao, Julie ^a   Stallone, John N ^b   Liang, Yu Mei ^a   Chen, Li Mei ^a   Wang, Dan Zhao ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Blood pressure; Kallikrein; Kallistatin; Renal pressure; Vasorelaxation

Indexed keywords

KALLIKREIN; KALLISTATIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG EFFECT; DRUG POTENCY; DRUG PURIFICATION; HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0030859291     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119502     Document Type: Article

References (29)

1. Bhoola, K.D., C.D. Figueroa, and K. Worthy. 1992. Bioregulation of kinins: kallikrein, kininogens, and kininases. Pharmacol. Rev. 44:1-80.
2. Margolius, H.S. 1989. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. Toxicol. 29:343-364.
3. Margolius, H.S. 1995. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension (Dallas). 26:221-229.
4. Regoli, D., and J. Barabe. 1980. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1-38.
5. Chao, J., K.X. Chai, L-M. Chen, W. Xiong, S. Chao, C. Woodley-Miller, L.X. Wang, H.S. Lu, and L. Chao. 1990. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J. Biol. Chem. 265:16394-16401.
6. Zhou, G.X., L. Chao, and J. Chao. 1992. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J. Biol. Chem. 267:25873-25880.
7. Chai, K.X., L-M. Chen, J. Chao, and L. Chao. 1993. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J. Biol. Chem. 268:24498-24505.
8. Xiong, W., C.Q. Tang, G.X. Zhou, L. Chao, and J. Chao. 1992. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J. Lab. Clin. Med. 119:514-521.
9. Ma, J.X., R. Yang, J. Chao, and L. Chao. 1995. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J. Biol. Chem. 270:451-455.
10. Serveau, C., T. Moreau, G. X. Zhou, J. Chao, and F. Gauthier. 1992. Inhibition of rat tissue kallikrein gene family members by rat kallikrein-binding protein and alpha 1-proteinase inhibitor. FEBS (Fed. Eur. Biochem. Soc.) 309: 405-408
11. Chao, J., A. Schmaier, L.-M. Chen, R. Yang, and L. Chao. 1996. Kallistatin, a novel human tissue kallikrein inhibitor: expression in blood cells and abnormal plasma level in human liver disease, sepsis and preeclampsia. J. Lab. Clin. Med. 127:612-620.
12. Chao, J., and L. Chao. 1995. Biochemistry, regulation and potential function of kallistatin. Hoppe-Seyler's Z. Physiol. Chem. 376:705-713.
13. Lu, H.S., F.K. Lin, L. Chao, and J. Chao. 1989. Human urinary kallikrein. Complete amino acid sequence and sites of glycosylation. Int. J. Pept. Protein Res. 33:237-249.
14. Wang, C., C. Tang, L. Chao, and J. Chao. 1992. Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim. Biophys. Acta. 1121:309-316.
15. Stallone, J.N. 1993. Role of endothelium in sexual dimorphism in vasopressin-induced contraction of rat aorta. Am. J. Physiol. 265:H2073-H2080.
16. Malik, K.U., and J.C. McGiff. 1975. Modulation by prostaglandin adrenergic transmission in the isolated perfused rabbit and rat kidney. Circ. Res. 36: 599-609.
17. Cooper, C.L., and K.U. Malik. 1984. Mechanism of action of vasopressin on prostaglandin synthesis and vascular function in the isolated rat kidney: effect of calcium antagonists and calmodulin inhibitors. J. Pharmacol. Exp. Ther. 229:139-147.
18. Burton, R.D., and J.N. Stallone. 1996. Sexual dimorphism in renal vascular reactivity to angiotensin in the spontaneously hypertensive rats: effects of gonadectomy and estrogen replacement. FASEB (Fed. Am. Soc. Exp. Biol.) J. 10:A708. (Abstr.)
19. Wirth, K., F.J. Hock, U. Albus, W. Linz, H.G. Alpermann, H. Anagnostopoulos, S.T. Henke, G. Breipohl, W. Konig, J. Knolle, and B.A. Scholkens. 1991. Hoe 140, a new potent and long acting bradykinin-antagonist in in vivo studies Br. J. Pharmacol. 102:774-777.
20. Wassdal, I., R. Hull, V.P. Gerskowitch, and T. Berg. 1995. Kallikrein rK10-induced kinin-independent, direct activation of NO-formation and relaxation of rat isolated aortic rings. Br. J. Pharmacol. 115:356-360.
21. Dixon, B.S. 1994. Cyclic cAMP selectively enhances bradykinin receptor synthesis and expression in cultured arterial smooth muscle. J. Clin. Invest. 93:2535-2544.
22. Linz, W., G. Wiemer, P. Gohlke, T. Unger, and B.A. Schölkens. 1995. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47:25-49.
23. Stallone, J.N. 1994. Sex differences in nitric oxide-mediated attenuation of vascular reactivity to vasopressin are abolished by gonadectomy. Eur. J. Pharmacol. 259:273-283.
24. G-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br. J. Pharmacol. 99: 408-412.
25. Chao, J., and L. Chao. 1988. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J. Hyperten. 6: 551-557.
26. Lindpaintner, K., K.X. Chai, R. Kreutz, N. Hubner, D. Ganten, L. Chao, and J. Chao. 1994. Identification of a major genetic locus linked sodium-sensitivity in genetically hypertensive rats. Hypertension (Dallas). 24:387.
27. Madeddu, P., J. Chao, L. Chao, M. Soregaroli, A. Valcamonico, L. Valsecchi, N. Glorioso, and T. Frusca. 1995. Urinary levels of kallikrein and kallistatin in pregnancy-induced hypertension. Hypertension in Pregnancy. 14: 1-12.
28. Chen, L.M., J.X. Ma, Y.M. Liang, L. Chao, and J. Chao. 1996. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J. Biol. Chem. 271:27590-27594.
29. Chen, L.M., L. Chao, and J. Chao. 1997. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Human Gene Therapy. 8:341-347.